

# Chris J Packard

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3538294/publications.pdf>

Version: 2024-02-01

59  
papers

10,559  
citations

117625

34  
h-index

138484

58  
g-index

60  
all docs

60  
docs citations

60  
times ranked

12414  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of <i>PNPLA3</i> I148M on hepatic lipid and veryâ€lowâ€density lipoprotein metabolism in humans. <i>Journal of Internal Medicine</i> , 2022, 291, 218-223.	6.0	5
2	Remnants, LDL, and the Quantification of Lipoprotein-Associated Risk in Atherosclerotic Cardiovascular Disease. <i>Current Atherosclerosis Reports</i> , 2022, 24, 133-142.	4.8	17
3	Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia. <i>Nature Reviews Cardiology</i> , 2022, 19, 577-592.	13.7	59
4	Role of endogenous incretins in the regulation of postprandial lipoprotein metabolism. <i>European Journal of Endocrinology</i> , 2022, 187, 75-84.	3.7	2
5	Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 962-975.	2.4	18
6	Effects of liraglutide on the metabolism of triglycerideâ€rich lipoproteins in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1191-1201.	4.4	20
7	LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial. <i>Atherosclerosis</i> , 2021, 320, 1-9.	0.8	11
8	Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges. <i>Heart</i> , 2021, 107, 1369-1375.	2.9	53
9	Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003219.	3.6	4
10	SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. <i>European Heart Journal</i> , 2021, 42, 2439-2454.	2.2	491
11	Keeping remnants in perspective. <i>European Heart Journal</i> , 2021, 42, 4333-4335.	2.2	13
12	Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategiesâ€a consensus statement from the European Atherosclerosis Society. <i>European Heart Journal</i> , 2021, 42, 4791-4806.	2.2	303
13	Triglyceride lowering 2.0: back to the future?. <i>European Heart Journal</i> , 2020, 41, 95-98.	2.2	7
14	Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects. <i>Journal of Clinical Lipidology</i> , 2020, 14, 77-87.	1.5	26
15	The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans. <i>Frontiers in Endocrinology</i> , 2020, 11, 474.	3.5	81
16	Targeting RNA With Antisenseâ€Oligonucleotides and Smallâ€Interfering RNA in Dyslipidemias. <i>Journal of the American College of Cardiology</i> , 2020, 76, 563-579.	2.8	52
17	Causes and Consequences of Hypertriglyceridemia. <i>Frontiers in Endocrinology</i> , 2020, 11, 252.	3.5	122
18	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2020, 41, 2313-2330.	2.2	776

#	ARTICLE	IF	CITATIONS
19	Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans. JCI Insight, 2020, 5, .	5.0	38
20	Letter by Packard Regarding Article, “Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial” Circulation, 2020, 142, e333-e334.	1.6	0
21	Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence. Current Atherosclerosis Reports, 2019, 21, 41.	4.8	53
22	Dietary Fructose and the Metabolic Syndrome. Nutrients, 2019, 11, 1987.	4.1	152
23	Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2019, 322, 1381.	7.4	144
24	Association of Triglyceride-Lowering <i>LPL</i> Variants and LDL-“Lowering <i>LDLR</i> Variants With Risk of Coronary Heart Disease. JAMA - Journal of the American Medical Association, 2019, 321, 364.	7.4	460
25	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet, The, 2019, 393, 407-415.	13.7	512
26	Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD. Current Atherosclerosis Reports, 2019, 21, 27.	4.8	72
27	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMÎ±) paradigm: conceptual framework and therapeutic potential. Cardiovascular Diabetology, 2019, 18, 71.	6.8	104
28	Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia. Diabetes, Obesity and Metabolism, 2019, 21, 1861-1870.	4.4	39
29	Strategies to alter the trajectory of atherosclerotic cardiovascular disease. Current Opinion in Lipidology, 2019, 30, 438-445.	2.7	4
30	LDL cholesterol: How low to go?. Trends in Cardiovascular Medicine, 2018, 28, 348-354.	4.9	12
31	Plasma apolipoprotein-B is an important risk factor for cardiovascular disease, and its assessment should be routine clinical practice. Current Opinion in Lipidology, 2018, 29, 51-52.	2.7	14
32	“Highest risk” “highest benefit”™ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies. European Heart Journal, 2018, 39, 2546-2550.	2.2	69
33	Association of oily fish intake, sex, age, BMI and <i>APOE</i> genotype with plasma long-chain<i>n</i>-3 fatty acid composition. British Journal of Nutrition, 2018, 120, 23-32.	2.3	15
34	Response by Vallejo-Vaz et al to Letters Regarding Article, “Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up” Circulation, 2018, 137, 2419-2420.	1.6	1
35	Determinants of Achieved LDL Cholesterol and “Non-HDL” Cholesterol in the Management of Dyslipidemias. Current Cardiology Reports, 2018, 20, 60.	2.9	8
36	Association of <i>LPA</i> Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies. JAMA Cardiology, 2018, 3, 619.	6.1	428

#	ARTICLE	IF	CITATIONS
37	Relationship between circulating microRNA-30c with total- and LDL-cholesterol, their circulatory transportation and effect of statins. <i>Clinica Chimica Acta</i> , 2017, 466, 13-19.	1.1	16
38	Unpacking and Understanding the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Apolipoprotein B Metabolism. <i>Circulation</i> , 2017, 135, 363-365.	1.6	8
39	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2017, 38, 2459-2472.	2.2	2,292
40	Modelling total coronary heart disease burden and long-term benefit of cholesterol lowering in middle aged men with and without a history of cardiovascular disease. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2017, 3, 281-288.	4.0	2
41	Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1949-1952.	0.9	63
42	Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above. <i>Circulation</i> , 2017, 136, 1878-1891.	1.6	144
43	Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 947.	7.4	247
44	High-Sensitivity Cardiac Troponin, Statin Therapy, and Risk of Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2719-2728.	2.8	199
45	Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy. <i>Circulation</i> , 2016, 133, 1073-1080.	1.6	190
46	Consumption of Fish Oil Providing Amounts of Eicosapentaenoic Acid and Docosahexaenoic Acid That Can Be Obtained from the Diet Reduces Blood Pressure in Adults with Systolic Hypertension: A Retrospective Analysis. <i>Journal of Nutrition</i> , 2016, 146, 516-523.	2.9	56
47	Long-term follow-up of lipid-lowering trials. <i>Current Opinion in Lipidology</i> , 2015, 26, 572-579.	2.7	18
48	Genome of the Netherlands population-specific imputations identify an ABCA6 variant associated with cholesterol levels. <i>Nature Communications</i> , 2015, 6, 6065.	12.8	45
49	Inheritance of coronary artery disease in men: an analysis of the role of the Y chromosome. <i>Lancet, The</i> , 2012, 379, 915-922.	13.7	179
50	Major Lipids, Apolipoproteins, and Risk of Vascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 1993.	7.4	2,205
51	Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target. <i>Current Opinion in Cardiology</i> , 2009, 24, 358-363.	1.8	35
52	A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease. <i>Atherosclerosis Supplements</i> , 2006, 7, 21-29.	1.2	6
53	A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractions. <i>Journal of Lipid Research</i> , 2005, 46, 58-67.	4.2	108
54	Non-HDL Cholesterol as a Measure of Atherosclerotic Risk. <i>Journal of Atherosclerosis and Thrombosis</i> , 2004, 11, 6-14.	2.0	77

#	ARTICLE	IF	CITATIONS
55	UK Food Standards Agency cis-monounsaturated fatty acid workshop report. British Journal of Nutrition, 2002, 88, 99-104.	2.3	14
56	Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Atherosclerosis, 2002, 164, 129-145.	0.8	81
57	Lipid-lowering drug therapies: the evidence. Proceedings of the Nutrition Society, 2000, 59, 423-424.	1.0	0
58	Lipoprotein Heterogeneity and Apolipoprotein B Metabolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 3542-3556.	2.4	352
59	Smoking and Plasma Lipoprotein Metabolism. Clinical Science, 1995, 89, 333-342.	4.3	35